微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 24.24% | 12.4% | 23.23% | 126/158 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 19.67% | -10.95% | 38.29% | 137/158 | 51.8% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 14.23% | -38.23% | -18.16% | 143/158 | 22.73% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 17.38% | -22.08% | -19.4% | 142/158 | 33.18% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 21.57% | 7.13% | -2.37% | 137/158 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 22.09% | -3.38% | -4.09% | 138/158 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 23.03% | -2.35% | 3.24% | 135/158 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 22.31% | -13.12% | 10.81% | 134/158 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 20.13% | -25.29% | -11.94% | 133/158 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 22.86% | -13.35% | -3.06% | 137/158 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 23.59% | -9.96% | -8.15% | 129/158 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 25.68% | -3.99% | -4.71% | 131/158 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 26.95% | 2.95% | 2.13% | 121/158 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 26.39% | 15.84% | 0.73% | 135/158 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 26.19% | 2% | -2.06% | 121/158 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 26.74% | 21.27% | 2.17% | 128/158 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 26.18% | 2% | 14.92% | 112/158 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 22.78% | -19.61% | 3.28% | 135/158 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 22.05% | 2% | -22.16% | 121/158 | 54.11% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-12-31 | 28.33% | -5.4% | -5.4% | 120/158 | -1222.98% | 微芯生物 | 95.14% | 行业排名> |
| 2018-12-31 | 29.95% | -2.01% | -2.01% | 116/158 | -208.09% | 多瑞医药 | 95.59% | 行业排名> |
| 2017-12-31 | 30.56% | 2% | 2% | 101/158 | 52.32% | 微芯生物 | 95.81% | 行业排名> |